Your session is about to expire
← Back to Search
CBD Oral Disintegrating Tablet (ODT) for Postoperative Pain
Study Summary
This trial will compare CBD to a placebo and opioids for post-operative pain management in shoulder surgery patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 & 3 trial • 100 Patients • NCT04672252Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Is there still space available for participants in this clinical experiment?
"The clinicaltrial.gov website reveals that this medical trial is not presently looking for any more participants. This research was first published on the 1st of December 2020 and its most recent update occured on August 2nd 2022. Though there are no open slots in this study, 483 others trials remain actively recruiting individuals at present."
Who meets the criteria to join this experiment?
"To be eligible for this clinical trial, potential patients must experience pain postoperatively and fall between the ages of 18-75. At present, 99 individuals are being sought out to participate in the study."
Does the study's parameters permit octogenarians to participate?
"The minimum and maximum ages for eligibility in this trial are 18 and 75 respectively, as specified by the inclusion criteria."
Has the FDA given their seal of approval to CBD Oral Disintegrating Tablet (ODT)?
"Since limited information is available on the safety and efficacy of CBD Oral Disintegrating Tablet (ODT), it scored a 1 out of 3."
Share this study with friends
Copy Link
Messenger